H M Verheul
Overview
Explore the profile of H M Verheul including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
20
Citations
580
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Dekker J, Beekman A, Boenink A, Bomhof-Roordink H, Braamse A, Collette E, et al.
Br J Cancer
. 2013 Jun;
108(12):2628-30.
PMID: 23756863
No abstract available.
2.
Caponi S, Funel N, Frampton A, Mosca F, Santarpia L, Van der Velde A, et al.
Ann Oncol
. 2012 Nov;
24(3):734-41.
PMID: 23139258
Background: This multicenter study evaluated three candidate microRNAs (miRNAs) (miR-21, miR-155 and miR-101) as potential biomarkers in intraductal papillary mucinous neoplasms (IPMNs) of the pancreas. Patients And Methods: miRNA expression...
3.
Giovannetti E, Labots M, Dekker H, Galvani E, Lind J, Sciarrillo R, et al.
Curr Pharm Des
. 2012 Sep;
19(5):927-39.
PMID: 22973961
Combination of drugs with different targets is a logical approach to overcome multilevel cross-stimulation among key pathways in NSCLC progression such as EGFR, K-Ras and VEGFR. The sorafenib-erlotinib combination showed...
4.
Honeywell R, Yarzadah K, Giovannetti E, Losekoot N, Smit E, Walraven M, et al.
J Chromatogr B Analyt Technol Biomed Life Sci
. 2010 Apr;
878(15-16):1059-68.
PMID: 20382575
A fast, sensitive, universal and accurate method for the determination of four different tyrosine kinase inhibitors from biological material was developed using LC-MS/MS techniques. Utilizing a simple protein precipitation with...
5.
Adema A, Laan A, Myhren F, Fichtner I, Verheul H, Sandvold M, et al.
Int J Oncol
. 2009 Dec;
36(1):285-94.
PMID: 19956857
To bypass resistance due to limited entry into the cell derivatives of cytarabine (CP-4055, elacytarabine) and gemcitabine (CP-4126) containing a fatty acid chain at the 5' position of the nucleoside...
6.
Adema A, Bijnsdorp I, Sandvold M, Verheul H, Peters G
Curr Med Chem
. 2009 Nov;
16(35):4632-43.
PMID: 19903145
Many drugs that are currently used for the treatment of cancer have limitations, such as induction of resistance and/or poor biological half-life, which reduce their clinical efficacy. To overcome these...
7.
Heideman D, Thunnissen F, Doeleman M, Kramer D, Verheul H, Smit E, et al.
Cell Oncol
. 2009 Sep;
31(5):329-33.
PMID: 19759413
Background: Increasing data from clinical trials support EGFR and K-ras mutation status as predictive markers of tumour response to EGFR-targeted therapies. Consequently, rapid and reliable mutation screening assays are demanded...
8.
Verheul H, Pinedo H
Clin Breast Cancer
. 2002 Apr;
1 Suppl 1:S80-4.
PMID: 11970755
Angiogenesis, or the formation of new blood vessels from preexisting vasculature, plays a major role in tumor growth and metastasis formation. Therefore, inhibiting tumor angiogenesis may be a promising therapeutic...
9.
Verheul H, Jorna A, Hoekman K, Broxterman H, Gebbink M, Pinedo H
Blood
. 2000 Dec;
96(13):4216-21.
PMID: 11110694
Coagulation abnormalities, including an increased platelet turnover, are frequently found in patients with cancer. Because platelets secrete angiogenic factors on activation, this study tested the hypothesis that platelets contribute to...
10.
Verheul H, Hoekman K, Jorna A, Smit E, Pinedo H
Oncologist
. 2000 May;
5 Suppl 1:45-50.
PMID: 10804091
Primary Purpose: Formation of ascites and pleural effusion (PE) is a common problem for patients with advanced-stage cancer. These fluid accumulations cause severe symptoms such as abdominal distention, shortness of...